Skip to content

Prediction of Intraventricular Hemorrhage Using Echocardiography and Near Infrared Spectroscopy

Intraventricular Hemorrhage of Newborn Grade 2 | Intraventricular Haemorrhage Grade...

Moderate-severe intraventricular hemorrhage (msIVH, Grades II-IV) is a significant neurological complication among extremely low gestational age neonates (ELGANs, \<=27+6 weeks) and is associated with long-term neuro-disabilities. In Canada, msIVH affects \~25-30% of the 1300 ELGANs born annually, with little change in incidence over last decade. Typically, it occurs between days 2-7 of age, providing a finite window of opportunity. Instituting therapies at the population level, however, exposes many low-risk infants to side effects, adversely affecting risk-benefit profile and requiring large sample sizes in trials. A targeted preventative approach, though ideal, is currently challenged by our inability to reliably identify at-risk ELGANs early after birth. Near-infrared spectroscopy (NIRS) has emerged as a promising non-invasive bedside neuromonitoring tool. Pilot studies using NIRS, including ours, found lower cerebral saturations (CrSO2) and greater periods of altered cerebral autoregulation in infants who later developed msIVH. However, a systematic planned investigation is needed to establish the predictive characteristics of NIRS-derived markers, using clinically translatable methods (cumulative burden over time-period vs. single time-point values) and identify their relative performance at different time-points during transition. Further, incorporating echocardiographic (ECHO) hemodynamic markers, known to be associated with msIVH, may allow for the establishment of robust multi-model prediction models and the gain of mechanistic hemodynamic insights to inform future management. Hence, our objective is to investigate the utility of multi-modal assessment using NIRS and ECHO for early identification of ELGANs at risk of msIVH, and generate clinically applicable predictive model(s).

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    0 and up

Critères de participation

Inclusion Criteria:

* Preterm infants born \<=27+6 weeks gestational age

Exclusion Criteria:

* Known genetic or congenital anomalies that are likely to affect cardiac or cerebral oxygenation measures
* Palliative care plan prior to or immediately following delivery

Lieu de l'étude

London Health Sciences Centre
London Health Sciences Centre
London, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Soume Bhattacharya

Foothillls Medical Centre
Foothillls Medical Centre
Calgary, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Lara Leijser

Mount Sinai Hospital
Mount Sinai Hospital
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Backup Contact

Phoebe Thum, MSc

[email protected]
Primary Contact

Thaiani Wulff

[email protected]
Royal Alexandra Hospital
Royal Alexandra Hospital
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Abbas Hyderi

Étude parrainée par
Mount Sinai Hospital, Canada
Participants recherchés
Plus d'informations
ID de l'étude: NCT05708105